BRIEF-Medicenna Presents Updated Results Of Single Agent MDNA11 Anti-Tumor Activity From Dose Escalation And Ongoing Dose Expansion Of The Phase 1/2 ABILITY-1 Study At The 2024 Annual Meeting Of The American Association For Cancer Research

Reuters04-10

April 9 (Reuters) - Medicenna Therapeutics Corp

* MEDICENNA PRESENTS UPDATED RESULTS OF SINGLE AGENT MDNA11 ANTI-TUMOR ACTIVITY FROM DOSE ESCALATION AND ONGOING DOSE EXPANSION OF THE PHASE 1/2 ABILITY-1 STUDY AT THE 2024 ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)

* MEDICENNA THERAPEUTICS CORP - DURABLE STABLE DISEASE $(SD)$ IN 3 MELANOMA PATIENTS FOR 6 TO 18 MONTHS WITH CONCOMITANT TUMOR SHRINKAGE

* MEDICENNA THERAPEUTICS CORP - MDNA11 IS GENERALLY WELL TOLERATED WITH NO DOSE-LIMITING TOXICITIES OR VASCULAR LEAK SYNDROME REPORTED IN ANY OF DOSE ESCALATION COHORTS

* MEDICENNA THERAPEUTICS CORP - 100% REDUCTION OF TARGET LESIONS IN ONE MELANOMA AND ONE PANCREATIC CANCER PATIENT OBSERVED AMONG 4 PR TO DATE

* MEDICENNA THERAPEUTICS - NEW SITES IN US & KOREA STARTED ENROLMENT IN ONGOING MONOTHERAPY EXPANSION & COMBINATION ESCALATION ARMS OF ABILITY-1 STUDY

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426904124?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-10 05:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426904124","market":"us","top_or_hot":-1,"title":"BRIEF-Medicenna Presents Updated Results Of Single Agent MDNA11 Anti-Tumor Activity From Dose Escalation And Ongoing Dose Expansion Of The Phase 1/2 ABILITY-1 Study At The 2024 Annual Meeting Of The American Association For Cancer Research","media":"Reuters","content":"<html><body><p>April 9 (Reuters) - <a href=\"https://laohu8.com/S/MDNA\">Medicenna Therapeutics Corp</a></p><p> :</p><p>   * MEDICENNA PRESENTS UPDATED RESULTS OF SINGLE AGENT MDNA11 ANTI-TUMOR ACTIVITY FROM DOSE ESCALATION AND ONGOING DOSE EXPANSION OF THE PHASE 1/2 ABILITY-1 STUDY AT THE 2024 ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)</p><p>   * MEDICENNA THERAPEUTICS CORP - DURABLE STABLE DISEASE <a href=\"https://laohu8.com/S/SD\">$(SD)$</a> IN 3 MELANOMA PATIENTS FOR 6 TO 18 MONTHS WITH CONCOMITANT TUMOR SHRINKAGE</p><p>   * MEDICENNA THERAPEUTICS CORP - MDNA11 IS GENERALLY WELL TOLERATED WITH NO DOSE-LIMITING TOXICITIES OR VASCULAR LEAK SYNDROME REPORTED IN ANY OF DOSE ESCALATION COHORTS</p><p>   * MEDICENNA THERAPEUTICS CORP - 100% REDUCTION OF TARGET LESIONS IN ONE MELANOMA AND ONE PANCREATIC CANCER PATIENT OBSERVED AMONG 4 PR TO DATE</p><p>   * MEDICENNA THERAPEUTICS - NEW SITES IN US &amp; KOREA STARTED ENROLMENT IN ONGOING MONOTHERAPY EXPANSION &amp; COMBINATION ESCALATION ARMS OF ABILITY-1 STUDY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Medicenna Presents Updated Results Of Single Agent MDNA11 Anti-Tumor Activity From Dose Escalation And Ongoing Dose Expansion Of The Phase 1/2 ABILITY-1 Study At The 2024 Annual Meeting Of The American Association For Cancer Research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Medicenna Presents Updated Results Of Single Agent MDNA11 Anti-Tumor Activity From Dose Escalation And Ongoing Dose Expansion Of The Phase 1/2 ABILITY-1 Study At The 2024 Annual Meeting Of The American Association For Cancer Research\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-10 05:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 9 (Reuters) - Medicenna Therapeutics Corp :   * MEDICENNA PRESENTS UPDATED RESULTS OF SINGLE AGENT MDNA11 ANTI-TUMOR ACTIVITY FROM DOSE ESCALATION AND ONGOING DOSE EXPANSION OF THE PHASE 1/2 ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SD","symbol_name":"SandRidge Energy","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2426904124","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426904124","pubTimestamp":1712697967,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 9  - Medicenna Therapeutics Corp :   * MEDICENNA PRESENTS UPDATED RESULTS OF SINGLE AGENT MDNA11 ANTI-TUMOR ACTIVITY FROM DOSE ESCALATION AND ONGOING DOSE EXPANSION OF THE PHASE 1/2 ABILITY-1 STUDY AT THE 2024 ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH    * MEDICENNA THERAPEUTICS CORP - DURABLE STABLE DISEASE  IN 3 MELANOMA PATIENTS FOR 6 TO 18 MONTHS WITH CONCOMITANT TUMOR SHRINKAGE   * MEDICENNA THERAPEUTICS CORP - MDNA11 IS GENERALLY WELL TOLERATED WITH NO DOSE-LIMITING TOXICITIES OR VASCULAR LEAK SYNDROME REPORTED IN ANY OF DOSE ESCALATION COHORTS   * MEDICENNA THERAPEUTICS CORP - 100% REDUCTION OF TARGET LESIONS IN ONE MELANOMA AND ONE PANCREATIC CANCER PATIENT OBSERVED AMONG 4 PR TO DATE   * MEDICENNA THERAPEUTICS - NEW SITES IN US & KOREA STARTED ENROLMENT IN ONGOING MONOTHERAPY EXPANSION & COMBINATION ESCALATION ARMS OF ABILITY-1 STUDYSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SD":"SandRidge Energy","AFG":"美国金融集团有限公司","BK4117":"多元化保险","BK4107":"财产与意外伤害保险","BK4213":"石油与天然气的勘探与生产","ABIL":"Ability Inc"},"translate_title":"简报——Medicenna在2024年美国癌症研究协会年会上介绍了单药MDNA11抗肿瘤活性的最新结果，这些结果来自1/2期ABILITY-1研究的剂量递增和正在进行的剂量扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABIL":1,"AFG":1,"SD":1},"content_text":"April 9 (Reuters) - Medicenna Therapeutics Corp :   * MEDICENNA PRESENTS UPDATED RESULTS OF SINGLE AGENT MDNA11 ANTI-TUMOR ACTIVITY FROM DOSE ESCALATION AND ONGOING DOSE EXPANSION OF THE PHASE 1/2 ABILITY-1 STUDY AT THE 2024 ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)   * MEDICENNA THERAPEUTICS CORP - DURABLE STABLE DISEASE $(SD)$ IN 3 MELANOMA PATIENTS FOR 6 TO 18 MONTHS WITH CONCOMITANT TUMOR SHRINKAGE   * MEDICENNA THERAPEUTICS CORP - MDNA11 IS GENERALLY WELL TOLERATED WITH NO DOSE-LIMITING TOXICITIES OR VASCULAR LEAK SYNDROME REPORTED IN ANY OF DOSE ESCALATION COHORTS   * MEDICENNA THERAPEUTICS CORP - 100% REDUCTION OF TARGET LESIONS IN ONE MELANOMA AND ONE PANCREATIC CANCER PATIENT OBSERVED AMONG 4 PR TO DATE   * MEDICENNA THERAPEUTICS - NEW SITES IN US & KOREA STARTED ENROLMENT IN ONGOING MONOTHERAPY EXPANSION & COMBINATION ESCALATION ARMS OF ABILITY-1 STUDYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426904124"}